Experience

Davis Polk advised the sole book-running manager on an SEC-registered offering by Celgene Corporation of $500 million aggregate principal amount of 2.250% senior notes due 2021. …

Davis Polk advised the representative of the underwriters in connection with the $402.5 million public offering of 5,296,053 shares of common stock of Spark Therapeutics, Inc. The…

Davis Polk advised Accuray Incorporated in connection with a private exchange of approximately $47 million aggregate principal amount of its outstanding 3.50% convertible senior notes due…

Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of Sienna Biopharmaceuticals, Inc., including shares sold pursuant to…

Davis Polk advised Biotoscana Investments S.A. and the selling shareholders in connection with an initial public offering of 44,550,000 common shares, including common shares in the form of…

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with a series of refinancing transactions that are intended to improve liquidity, extend debt maturities and enable…

Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The…

Davis Polk advised the underwriters in connection with an initial public offering of 17,968,750 shares of common stock of Akcea Therapeutics, Inc., including shares sold pursuant to the…

Davis Polk advised the joint book-running managers in connection with the $86.3 million initial public offering of common stock of Dova Pharmaceuticals, Inc. The common stock is listed on…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $75 million initial public offering of common stock of Mersana Therapeutics…